Daniel Edquist, MD
Family Medicine · Laporte, INNPI 1295723542
Payments from drug & device makers
Across 175 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$454
- Boehringer Ingelheim$194
- GSK$163
- Pfizer$162
- Novartis$152
- Bayer$149
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,771100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $454 |
| Boehringer Ingelheim | 10 | $194 |
| GSK | 11 | $163 |
| Pfizer | 10 | $162 |
| Novartis | 10 | $152 |
| Bayer | 9 | $149 |
| Lilly USA, LLC | 7 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $132 |
| Boston Scientific | 2 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $122 |
| Astellas Pharma US Inc | 8 | $106 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Amgen | 5 | $70 |
| Dexcom, Inc. | 4 | $59 |
| Exact Sciences | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Mylan Specialty L.p. | 2 | $50 |
| AbbVie(2 entities) | 4 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Johnson & Johnson | 2 | $39 |
| AstraZeneca | 3 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Nevro Corp. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,771 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $65,460 |
| TrulicityDulaglutide | 24 | $38,808 |
| OzempicSemaglutide | 13 | $30,753 |
| EliquisApixaban | 52 | $30,231 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $19,739 |
| FarxigaDapagliflozin Propanediol | 22 | $19,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,707 |
| XareltoRivaroxaban | 13 | $18,046 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $14,319 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $9,643 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,396 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,773 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $6,519 |
| Atorvastatin Calcium | 671 | $3,966 |
| Levetiracetam | 148 | $3,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $194 | $72,23379 claims |
| Lilly USA, LLCTrulicity | $145 | $38,80824 claims |
| PfizerEliquis, Lyrica | $162 | $32,20265 claims |
| Novo NordiskOzempic | $454 | $30,75313 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $163 | $28,10233 claims |
| AstraZenecaFarxiga | $38 | $19,04922 claims |
| Johnson & JohnsonXarelto | $39 | $18,04613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Laporte
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.